Enclomiphene and RAD-140 Interaction

Compatible
Researched 90% confidence

Enclomiphene and RAD-140 have a compatible interaction with 90% confidence. Enclomiphene is commonly used as part of post-cycle therapy (PCT) following RAD-140 cycles to restore endogenous testosterone production. Typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks starting 2-3 days after the last RAD-140 dose (accounting for its long half-life, a delayed start of 5-7 days may also be appropriate). Both compounds affect the gonads, so monitoring these systems is recommended.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Half-life: ~10 hours Typical dose: 12.5-25mg oral daily pct, sexual health
estrogen receptorserotonin receptor hepatotoxicpct agentteratogenic
View full profile

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Half-life: ~60 hours Typical dose: 10-20 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskcrosses bbb
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Enclomiphene, RAD-140). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take Enclomiphene with RAD-140?

Yes, Enclomiphene and RAD-140 can generally be taken together. Enclomiphene is commonly used as part of post-cycle therapy (PCT) following RAD-140 cycles to restore endogenous testosterone production. Typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks starting 2-3 days after the last RAD-140 dose (accounting for its long half-life, a delayed start of 5-7 days may also be appropriate).

Is Enclomiphene and RAD-140 safe together?

Based on documented research, this combination is considered compatible. However, shared safety flags include: hepatotoxic. Monitor accordingly.

What are the interactions between Enclomiphene and RAD-140?

Enclomiphene is commonly used as part of post-cycle therapy (PCT) following RAD-140 cycles to restore endogenous testosterone production. Typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks starting 2-3 days after the last RAD-140 dose (accounting for its long half-life, a delayed start of 5-7 days may also be appropriate). This assessment has 90% confidence and is based on documented research data.

How should I time Enclomiphene and RAD-140?

Enclomiphene has a half-life of ~10 hours and RAD-140 has a half-life of ~60 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Enclomiphene vs RAD-140

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.